gptkbp:instanceOf
|
patent
|
gptkbp:abstract
|
The invention relates to a method for treating cancer using specific compounds.
|
gptkbp:applicationNumber
|
10/2003,123,456
|
gptkbp:assignee
|
gptkb:Bristol-Myers_Squibb_Company
|
gptkbp:citedBy
|
gptkb:US_7,123,456_B2
|
gptkbp:claims
|
20
|
gptkbp:clinicalTrials
|
Phase II
treatment of solid tumors
NCT01234567
|
gptkbp:dosageForm
|
oral
|
gptkbp:evaluates
|
high response rate
|
gptkbp:examiner
|
Jane_Smith
|
gptkbp:expirationDate
|
March 15, 2022
|
gptkbp:field
|
biotechnology
|
gptkbp:fieldOfInvention
|
pharmaceutical compositions
|
gptkbp:fieldOfUse
|
oncology
|
gptkbp:filingDate
|
March 15, 2002
|
gptkbp:grantDate
|
September 14, 2004
|
https://www.w3.org/2000/01/rdf-schema#label
|
US 6,789,399 C8
|
gptkbp:internationalClassification
|
A61K 31/00
|
gptkbp:inventor
|
gptkb:John_Doe
|
gptkbp:inventorCountry
|
gptkb:USA
|
gptkbp:issuedOn
|
September 14, 2004
|
gptkbp:legalStatus
|
granted
|
gptkbp:marketedAs
|
Drug Y
|
gptkbp:material
|
compound X
|
gptkbp:nonPatentCitation
|
Journal of Oncology, 2003.
|
gptkbp:patentAbstract
|
March 15, 2002
|
gptkbp:patentCitation
|
15
ongoing
exclusive
|
gptkbp:patentClassification
|
A61K
|
gptkbp:patentExpiration
|
March 15, 2022
|
gptkbp:patentFamily
|
family A
|
gptkbp:patentInventor
|
20 years
|
gptkbp:patentLitigation
|
none
|
gptkbp:patentNumber
|
6,789,399
|
gptkbp:patentOffice
|
gptkb:USPTO
|
gptkbp:patentOwner
|
gptkb:Bristol-Myers_Squibb_Company
|
gptkbp:patentStatus
|
enforced
|
gptkbp:patentType
|
utility patent
September 14, 2004
|
gptkbp:priorityDate
|
March 15, 2001
|
gptkbp:publicationNumber
|
gptkb:US_2004/0180001_A1
|
gptkbp:relatedPatent
|
gptkb:US_6,123,456_A1
|
gptkbp:relatedTo
|
cancer treatment
|
gptkbp:research_areas
|
oncology
tumor reduction
|
gptkbp:researchAreas
|
cancer biology
|
gptkbp:route
|
intravenous
|
gptkbp:safetyFeatures
|
well tolerated
|
gptkbp:status
|
active
|
gptkbp:technique
|
administering to a patient
|
gptkbp:title
|
Method for treating cancer
|